ATE460407T1 - Kristalline formen von duloxetin als freie base - Google Patents

Kristalline formen von duloxetin als freie base

Info

Publication number
ATE460407T1
ATE460407T1 AT05744361T AT05744361T ATE460407T1 AT E460407 T1 ATE460407 T1 AT E460407T1 AT 05744361 T AT05744361 T AT 05744361T AT 05744361 T AT05744361 T AT 05744361T AT E460407 T1 ATE460407 T1 AT E460407T1
Authority
AT
Austria
Prior art keywords
duloxetine
free base
crystalline forms
crystalline
forms
Prior art date
Application number
AT05744361T
Other languages
English (en)
Inventor
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Pathi L Srinivas
Puppala Ravikumar
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32526812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE460407(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of ATE460407T1 publication Critical patent/ATE460407T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AT05744361T 2004-05-11 2005-05-11 Kristalline formen von duloxetin als freie base ATE460407T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410470.9A GB0410470D0 (en) 2004-05-11 2004-05-11 Pharmaceutical compound and polymorphs thereof
PCT/GB2005/001825 WO2005108386A1 (en) 2004-05-11 2005-05-11 Crystalline forms of duloxetine free base

Publications (1)

Publication Number Publication Date
ATE460407T1 true ATE460407T1 (de) 2010-03-15

Family

ID=32526812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05744361T ATE460407T1 (de) 2004-05-11 2005-05-11 Kristalline formen von duloxetin als freie base

Country Status (15)

Country Link
US (1) US7951837B2 (de)
EP (1) EP1745031B1 (de)
JP (1) JP5285272B2 (de)
KR (1) KR20070011593A (de)
AR (1) AR049093A1 (de)
AT (1) ATE460407T1 (de)
AU (1) AU2005240839B2 (de)
CA (1) CA2566092C (de)
DE (1) DE602005019873D1 (de)
ES (1) ES2340297T3 (de)
GB (1) GB0410470D0 (de)
NZ (1) NZ551125A (de)
PA (1) PA8632501A1 (de)
WO (1) WO2005108386A1 (de)
ZA (1) ZA200609205B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
TW200639162A (en) 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
WO2007038253A2 (en) 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate and methods of preparation thereof
EP1863782A1 (de) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamin)-3-(2-naphthol) thiophen, eine verunreinigung von duloxetin hydrochlorid
EP1971593A2 (de) * 2005-12-12 2008-09-24 Medichem, S.A. Verbesserte synthese und zubereitungen von duloxetinsalzen
CZ299270B6 (cs) 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP1820800A1 (de) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Kristalline Formen von Duloxetine hydrochlorid und Verfahren zu deren Herstellung
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
BRPI0711606A2 (pt) * 2006-05-22 2012-02-14 Teva Pharma formulações de hidrocloreto de duloxetina de liberação retardada
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612506D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
WO2010103443A1 (en) 2009-03-13 2010-09-16 Alembic Limited A process for the preparation of duloxetine hydrochloride
CZ304602B6 (cs) * 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets

Also Published As

Publication number Publication date
US20070167513A1 (en) 2007-07-19
AU2005240839A1 (en) 2005-11-17
ZA200609205B (en) 2008-08-27
EP1745031B1 (de) 2010-03-10
JP5285272B2 (ja) 2013-09-11
DE602005019873D1 (de) 2010-04-22
PA8632501A1 (es) 2006-07-03
AR049093A1 (es) 2006-06-28
KR20070011593A (ko) 2007-01-24
WO2005108386A1 (en) 2005-11-17
JP2007537223A (ja) 2007-12-20
ES2340297T3 (es) 2010-06-01
NZ551125A (en) 2010-08-27
US7951837B2 (en) 2011-05-31
CA2566092C (en) 2013-12-10
GB0410470D0 (en) 2004-06-16
CA2566092A1 (en) 2005-11-17
EP1745031A1 (de) 2007-01-24
AU2005240839B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
ATE460407T1 (de) Kristalline formen von duloxetin als freie base
DE602005012267D1 (de) N von geräten
FR2872069B1 (fr) Vibrateur vertical
ATE414693T1 (de) Neuartige cis-imidazoline
ATE494369T1 (de) Pektatlyasevarianten
ATE491700T1 (de) KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
EP1788874A4 (de) Salze von 5-azacytidin
DE60321190D1 (de) Knopf
DE502005007457D1 (de) Mikroemulsionen
DE602005027610D1 (de) Nmr-gyroskop
DE602005012984D1 (de) Suspensionspolymerisationsverfahren
NO20070299L (no) Novel heterocyclic compounds
DE602005019199D1 (de) Suspensionspolymerisationsverfahren
DE602005016475D1 (de) Knopf
DE502004009754D1 (de) Tourbillon
DE602005019087D1 (de) Suspensionspolymerisationsverfahren
DE502004009022D1 (de) Pendelstütze
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DE502005002684D1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
SE0402103D0 (sv) Novel compounds
ITPG20030013A1 (it) Pendolo bibarico a doppio stiramento
ATA18572003A (de) Analoguhr
FIU20040005U0 (fi) Poraniskan ylävaste
FIU20040172U0 (fi) Ripustusvarsi
ITRI20050001U1 (it) Kit dell'amatriciana

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties